Status: Available
Expanded Access Protocol of Viaskin® Peanut (DBV712) in Peanut-allergic Children
This is an open label expanded access program for male and female patients 2 years or older, to provide continued desensitization treatment with DBV712 250 mcg.
Trial details
Age: 2-17Biological sex: AllType: Expanded AccessSponsor: DBV TechnologiesUpdated: Jan 15, 2026Locations: 1
Eligibility criteria
Participation is by invitation, limited to individuals completing clinical study... [+2]
Early withdrawal from a DBV712 clinical study. [+3]